Therefore, we preliminarily selected SESN2 as a downstream target regulated by SND1, which has been reported to be downregulated in various cancers and to inhibit bladder cancer progression, but its role in PCa remains unclear [24, 37]. This evidence concerns the gene SESN2 and urinary bladder cancer.